Sponsors (3)
The bill shifts SBIR/STTR toward faster, more commercialization-focused support (funding flexibility, assistance, training, IP prioritization, and reporting) to help startups reach markets and attract investment — at the cost of added administrative burdens, potential reductions in direct R&D dollars, competitive and privacy risks for firms, and a reduced emphasis on non‑commercial/basic research.
SBIR/STTR awardees (especially small-business owners and researcher-entrepreneurs) gain substantially expanded commercialization supports and tools — including commercialization-focused peer review, designated technology commercialization officials (TCOs), targeted advocacy to Phase III markets, commercialization reporting, I‑Corps access, and technical/business assistance — increasing the chances
Small businesses receiving SBIR/STTR awards get faster award-decision timelines (statutory agency action shortened from 1 year to 180 days), giving companies quicker access to funding and reducing time-to-market for funded projects.
Award opportunities expand in the near term (FY2025–FY2027) through larger flexible-award authority across agencies and up to 30% NIH allocation to flexible awards, increasing available funding avenues for biomedical and other startups.
Researchers and projects with high scientific merit but limited near-term commercial prospects (including university labs and early-stage research teams) may lose relative access to SBIR/STTR funding as commercialization metrics and expertise are prioritized.
Federal agencies and the SBA face increased administrative, reporting, and data-collection burdens (designating TCOs, more peer-review complexity, biennial reporting, compiling firm-level metrics, USPTO coordination), likely raising program overhead and taxpayer costs if not separately funded.
Eligible small businesses must provide detailed multi-year financial and commercialization data, creating significant reporting burden and raising confidentiality and competitive-risk concerns if sensitive information is disclosed to Congress or publicly.
Based on analysis of 8 sections of legislative text.
Changes SBIR/STTR rules to prioritize commercialization, require agency TCOs and reporting, allow award funds for assistance/I‑Corps, cap expanded-phase awards, and add USPTO patent help.
Official title: To improve commercialization activities in the SBIR and STTR programs, and for other purposes.
Introduced May 7, 2025 by Christina Houlahan · Last progress May 7, 2025
Makes changes to the federal SBIR and STTR small-business research programs to speed review and commercialization, add commercialization expertise and reporting, expand agency flexibility for larger awards under caps, require agency Technology Commercialization Officials, permit award funds for technical/business assistance and I‑Corps participation, create an annual commercialization impact assessment, and set up USPTO partnership for prioritized patent help. The bill focuses on helping small companies move research to market faster and measuring outcomes across agencies.